SETD2 gene mutations have been identified in many cancers including kidney cancer (Cancer, 2013), pancreatic cancer (Niu et al., 2020a), prostate cancer (Yuan et al., 2020), leukemia (Dong et al., 2019), lung adenocarcinoma (Zhou Y et al., 2020), brain glioma (Fontebasso et al., 2013), breast cancer (Morcillo-Garcia et al., 2019), and gastrointestinal cancer (Chen et al., 2018). Here, SETD2 is linked to pancreatic neoplasm.